In last trading session, Prime Medicine Inc (NASDAQ:PRME) saw 5.6 million shares changing hands with its beta currently measuring 2.26. Company’s recent per share price level of $3.9 trading at -$0.14 or -3.47% at ring of the bell on the day assigns it a market valuation of $524.53M. That closing price of PRME’s stock is at a discount of -69.74% from its 52-week high price of $6.62 and is indicating a premium of 71.54% from its 52-week low price of $1.11. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 6.41 million shares which gives us an average trading volume of 3.29 million if we extend that period to 3-months.
For Prime Medicine Inc (PRME), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.73. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Prime Medicine Inc (NASDAQ:PRME) trade information
Prime Medicine Inc’s shares saw a change of -32.53% in year-to-date performance and have moved -16.84% in past 5-day. Prime Medicine Inc (NASDAQ:PRME) showed a performance of 160.00% in past 30-days. Number of shares sold short was 18.48 million shares which calculate 7.36 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 17 to the stock, which implies a rise of 77.06% to its current value. Analysts have been projecting 12 as a low price target for the stock while placing it at a high target of 23. It follows that stock’s current price would drop -207.69% in reaching the projected high whereas dropping to the targeted low would mean a loss of -207.69% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -124.13% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 23.78% while estimates for its earnings growth in next 5 years are of 18.47%.
Prime Medicine Inc (NASDAQ:PRME)’s Major holders
Insiders are in possession of 24.22% of company’s total shares while institution are holding 56.84 percent of that, with stock having share float percentage of 75.01%. Investors also watch the number of corporate investors in a company very closely, which is 56.84% institutions for Prime Medicine Inc that are currently holding shares of the company. ALPHABET INC. is the top institutional holder at PRME for having 15.06 million shares of worth $77.42 million. And as of 2024-06-30, it was holding 12.6375 of the company’s outstanding shares.
The second largest institutional holder is ARK INVESTMENT MANAGEMENT LLC, which was holding about 6.13 million shares on 2024-06-30. The number of shares represents firm’s hold over 5.1404 of outstanding shares, having a total worth of $31.49 million.
On the other hand, ARK ETF Trust-ARK Genomic Revolution ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 30, 2025 , the former fund manager was holding 2.27 shares of worth $8.84 million or 1.69% of the total outstanding shares. The later fund manager was in possession of 2.1 shares on Mar 31, 2025 , making its stake of worth around $8.17 million in the company or a holder of 1.56% of company’s stock.
